{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.200","value":"31"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Disease flare"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non-responder (protocol violation)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Treatment response was based on Physician's global assessment(PGA) of autoinflammatory disease activity, assessment of skin disease(SD) and serum values of C-reactive protein(CRP) and/or serum amyloid A(SAA). Complete Response (CR):PGA and SD ≤ minimal and normal CRP and/or SAA. Partial Response (PR): a reduction of CRP and/or SAA from baseline (BL) by \\>30% but not reaching normal values and PGA improvement from BL by at least one category. Disease flare: a CRP and/or SAA \\> 30 mg/L and either PGA \\> minimal or PGA = minimal and SD \\> minimal. Non-responders = no PR by Day 8 or no CR by Day 15.","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"8 weeks after study start","title":"Number of Participants With Treatment Response in Part I (After 8 Weeks)","type":"SECONDARY","unitOfMeasure":"Participants"}